type 1 diabetes

First Oral Drug for Type 1 Diabetes Could be Available in 2018
First Oral Drug for Type 1 Diabetes Could be Available in 2018
Xtalks
type 1 diabetes
sotagliflozin
Sanofi
Lexicon Pharmaceuticals
Flag link:
With an eye on the FDA, Lexicon and Sanofi line up more positive data on diabetes drug
With an eye on the FDA, Lexicon and Sanofi line up more positive data on diabetes drug
Endpoints
FDA
Lexicon Pharmaceuticals
Sanofi
type 1 diabetes
sotagliflozin
Flag link:
Provention Bio wants to stop Type I diabetes – with a vaccine
Provention Bio wants to stop Type I diabetes – with a vaccine
Drug Delivery Business News
Provention Bio
type 1 diabetes
vaccines
Flag link:
Lexicon Pharma Goes Three For Three With Sotagliflozin Data
Lexicon Pharma Goes Three For Three With Sotagliflozin Data
Seeking Alpha
Lexicon Pharmaceuticals
sotagliflozin
type 1 diabetes
Sanofi
Flag link:
Is Medtronic's Artificial Pancreas the Next Big Thing in Diabetes?
Is Medtronic's Artificial Pancreas the Next Big Thing in Diabetes?
Motley Fool
Medtronic
artificial pancreas
devices
diabetes
type 1 diabetes
MiniMed 670G
Flag link:
Lexicon developing type 1 diabetes treatment with Sanofi
Lexicon developing type 1 diabetes treatment with Sanofi
Medical Marketing and Media
Lexicon Pharmaceuticals
Sanofi
drug development
type 1 diabetes
Flag link:
Lexicon's Phase 2 Diabetes Study Looks Good
Lexicon's Phase 2 Diabetes Study Looks Good
Investopedia
Lexicon Pharmaceuticals
sotagliflozin
type 1 diabetes
diabetes
Flag link:
FDA approves Medtronic's 'artificial pancreas' for diabetes
FDA approves Medtronic's 'artificial pancreas' for diabetes
Reuters
FDA
Medtronic
artificial pancreas
type 1 diabetes
devices
MiniMed 670G
Flag link:
Pfizer seeds diabetes upstart AnTolRx with cash and an option deal
Pfizer seeds diabetes upstart AnTolRx with cash and an option deal
Endpoints
Pfizer
AnTolRx
diabetes
type 1 diabetes
Flag link:
JDRF backs Defymed for artificial pancreas study
JDRF backs Defymed for artificial pancreas study
Mass Device
diabetes
JDRF
artificial pancreas
Defymed
Mailpan
type 1 diabetes
devices
Flag link:
J&J's Invokana shines in PhII Type 1 diabetes study--but raises the risk of serious side effects, too
J&J's Invokana shines in PhII Type 1 diabetes study--but raises the risk of serious side effects, too
Fierce Pharma
JNJ
Invokana
type 1 diabetes
Janssen
Flag link:
Sanofi Joins Hands with JDRF for Breakthrough Diabetes Research
Sanofi Joins Hands with JDRF for Breakthrough Diabetes Research
Bidness, ETC
Sanofi
diabetes
JDRF
R&D
type 1 diabetes
Flag link:
J&J, Viacyte team up on a potential stem cell therapy 'cure' for type 1 diabetes
J&J, Viacyte team up on a potential stem cell therapy 'cure' for type 1 diabetes
BioPharma Dive
JNJ
ViaCyte
stem cells
type 1 diabetes
Flag link:
Novo pulls blockbuster diabetes med Victoza off the Type 1 track
Novo pulls blockbuster diabetes med Victoza off the Type 1 track
Fierce Pharma Marketing
Novo Nordisk
Victoza
diabetes
type 1 diabetes
Flag link:
Johnson & Johnson starts project to prevent Type 1 diabetes
Johnson & Johnson starts project to prevent Type 1 diabetes
Yahoo/AP
JNJ
type 1 diabetes
Flag link:
Roche’s Arthritis Blockbuster Holds Promise for Diabetes
Roche’s Arthritis Blockbuster Holds Promise for Diabetes
Bloomberg
Roche
type 1 diabetes
Actemra
Flag link:
The Stunning Mobile Game Changer for Diabetics That Investors Can't Ignore
The Stunning Mobile Game Changer for Diabetics That Investors Can't Ignore
Motley Fool
Apple
Medtronic
Guardian Mobile
diabetes
DexCom
Senseonics
type 1 diabetes
Flag link:
Sanofi Diabetes is on a Mission to Support Children, Parents and Carers of Children with Type 1 Diabetes through Gaming
Sanofi Diabetes is on a Mission to Support Children, Parents and Carers of Children with Type 1 Diabetes through Gaming
Yahoo
type 1 diabetes
Sanofi
Flag link:
Who Will Win This $45 Billion Market?
Who Will Win This $45 Billion Market?
Motley Fool
Sanofi
Novo Nordisk
diabetes
type 1 diabetes
type 2 diabetes
Flag link:
Lexicon Pharmaceuticals up 25% on drug trial
Lexicon Pharmaceuticals up 25% on drug trial
Marketwatch
Lexicon Pharmaceuticals
type 1 diabetes
LX4211
Flag link: